

Erratum

The main author and co-authors of Eyre et al (2017) wish to recognise Dr Arumainathan as an additional co-author. He provided substantial clinical data to the project and without his input the data collection would have been considerably less valuable. The main author of this article apologises for this incorrect and accidental omission and recognises the value of Dr Arumainathan's input and his value as a co-author.

The original published online article has been corrected. Arvind Arumainathan, Department of Haematology, Royal Liverpool University Hospital NHS Trust, Liverpool has been added to the authorship; and the subsequent authors' affiliations were re-numbered.

Reference

Eyre, T.A., Phillips, E.H., Linton, K.M., Arumainathan, A., Kassam, S., Gibb, A., Allibone, S., Radford, J., Peggs, K., Burton, C., Stewart, G., LeDieu, R., Booth, C., Osborne, W.L., Miall, F., Eyre, D.W., Ardeshta, K.M. & Collins, G.P. (2017) Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting. *British Journal of Haematology*, **179**, 471–479. <https://doi.org/10.1111/bjh.14898>